Kazuyoshi Sato
Overview
Explore the profile of Kazuyoshi Sato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azuma R, Sato K, Sunadoi H, Ishii Y, Tomaru U, Motohashi M
J Cardiothorac Surg
. 2023 Nov;
18(1):334.
PMID: 37974190
Background: Primary cardiac myxofibrosarcoma is rare and commonly occurs in the left atrium. Myxofibrosarcoma is aggressive and has a high mortality rate due to its high rate of recurrence. Complete...
2.
Tsukamoto S, Kobayashi K, Toyoda M, Hatori N, Kanaoka T, Wakui H, et al.
Hypertens Res
. 2023 Oct;
47(3):628-638.
PMID: 37848562
Sodium-glucose cotransporter 2 inhibitor (SGLT2-I) shows excellent antihypertensive effects in addition to its hypoglycemic effects. However, whether body mass index (BMI) affects the antihypertensive effect of SGLT2-I remains unknown. We...
3.
Kobayashi K, Toyoda M, Hatori N, Tsukamoto S, Kimura M, Sakai H, et al.
Cardiovasc Endocrinol Metab
. 2023 Oct;
12(4):e0292.
PMID: 37779602
Aims: This study aimed to clarify the renal influence of glucagon-like peptide 1 receptor agonists (GLP1Ras) with or without sodium-glucose co-transporter 2 inhibitors (SGLT2is) on Japanese patients with type 2...
4.
Kobayashi K, Chin K, Hatori N, Furuki T, Sakai H, Miyakawa M, et al.
Hypertens Res
. 2023 Aug;
46(11):2447-2459.
PMID: 37532949
We aim to assess the data of patients with hypertension in Kanagawa Prefecture, Japan, collected in 2021 that were provided by the Japan Medical Association Database of Clinical Medicine. Data...
5.
Li F, Kannari N, Maruyama J, Sato K, Abe H
J Hazard Mater
. 2023 Jan;
447:130803.
PMID: 36680901
Water pollution by dyes is one of the biggest environmental problems. Adsorption technology has been widely used in wastewater treatment. In this work, high-entropy concept is used to design surface...
6.
Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Sato K, et al.
Sci Rep
. 2022 Sep;
12(1):16106.
PMID: 36167964
The cardiovascular and renal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1Ras) are enhanced by low/controlled blood pressure (BP). However, the BP-lowering efficacy...
7.
Toyoda M, Saito N, Kimura M, Hatori N, Tamura K, Miyakawa M, et al.
J Diabetes Investig
. 2022 May;
13(9):1520-1527.
PMID: 35524473
Aims/introduction: We previously reported that sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment was associated with an improvement of the albumin-to-creatinine ratio in Japanese patients with type 2 diabetes mellitus and chronic...
8.
Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, et al.
Diabetes Res Clin Pract
. 2022 Feb;
185:109231.
PMID: 35131376
Aims: This study aimed to clarify the differences in how sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1Ra) influence kidney function in Japanese patients with...
9.
Kobayashi K, Toyoda M, Hatori N, Sato K, Miyakawa M, Tamura K, et al.
J Diabetes Res
. 2022 Jan;
2021:6573369.
PMID: 35028319
Methods: We retrospectively constructed database of 763 Japanese patients with T2DM and CKD who received sSGLT2is for more than 1 year. Among these SGLT2i-treated patients, 338 were receiving concomitant DPP4i...
10.
Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Hatori Y, et al.
Clin Transl Sci
. 2022 Jan;
15(4):1050-1062.
PMID: 34989473
Polypharmacy is a serious concern in general practice, especially among elder patients; however, the evidence showing significantly poor renal outcomes is not sufficient. This survey was performed to evaluate the...